Icosavax, Inc.
ICVX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.14 | -0.00 | 0.00 |
| FCF Yield | -23.08% | -9.62% | -14.13% | -1.28% |
| EV / EBITDA | -2.82 | -2.03 | -4.99 | -62.07 |
| Quality | ||||
| ROIC | -40.37% | -23.66% | -181.02% | -24.00% |
| Gross Margin | -216.67% | 98.95% | -993.25% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.58 | 0.75 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.85% | – | 1,173,392.86% | -100.00% |
| Free Cash Flow Growth | -84.06% | -178.12% | -211.21% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.53 | 4.30 | 0.44 | 4.28 |
| Interest Coverage | 0.00 | -436.17 | -56.53 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -572.75 | -17,355.30 | -39.63 | -70.16 |